Equity Research, Broker Reports, and media content on Kiadis Pharma NV

  • Access the latest forecasts, broker valuations, multiples, and video content from the city about Kiadis Pharma NV
  • See live updates from analysts, company announcements, and other news in a personalised/single dashboard

Kiadis Pharma NV

Company Profile

Research, Charts & Company Announcements

Research Tree provides access to ongoing research coverage, media content and regulatory news on Kiadis Pharma NV. We currently have 0 research reports from 0 professional analysts.

  • Open: N/A
  • Range Today: N/A
  • 52 Week: 510/1390c
  • Daily Volume: N/A
  • Daily Liquidity: 0.0%
  • # Shares: 0m
  • Market Cap: 215.4m
  • Latest PE (hist):
  • Div Yield:
Date Source Announcement
17Aug20 06:00 GNW Kiadis collaborates with premier Dutch institutions to apply K-NK-cell technology for the development of a novel COVID-19 therapy
06May20 07:00 GNW Kiadis Pharma announces U.S. FDA approval to start NK-REALM Phase 2 clinical trial for natural killer (NK) cell therapy produced with PM21
30Apr20 19:57 GNW Kiadis Pharma announces closing of two private placements totalling €17 million
30Apr20 16:35 GNW Kiadis Pharma announces annual results for the year ended December 31, 2019  
10Mar20 07:30 GNW Kiadis Pharma announces new data on ex-vivo FC21 expanded NK-cell therapy in 13 patients with relapsed/refractory acute myeloid leukemia will be presented at the European Society for Blood and Marrow Transplantation Annual Meeting*
04Mar20 07:30 GNW Kiadis Pharma to present at BioCapital Europe 2020
26Feb20 07:30 GNW Kiadis Pharma announces FDA clearance of clinical study by The Ohio State University in R/R AML with off-the-shelf NK cells from universal donors
  • Frequency of research reports


  • Research reports on

    Kiadis Pharma NV

  • Providers covering

    Kiadis Pharma NV